BCG Vaccines Sales Market by Drug Type (Immune BCG and Therapy BCG), Usage (Tuberculosis and Bladder Cancer), and End User (Pediatrics and Adults): Opportunity Analysis and Industry Forecast, 2018 - 2025

The global BCG vaccines sales market was valued at $45 million in 2017, and is estimated to reach $65 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.

BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. It is administered to newborns from tuberculosis and leprosy prevalent regions. This vaccine is generally administered to children at birth in countries with high incidence of TB. However, in low incidence regions, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

Major factors that drive the market growth are increase in the prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, increase in government initiatives and focus on immunization programs globally boost the market growth. However, side-effects and a global shortage of BCG vaccine restrain the market growth. Furthermore, untapped market potential in developing regions is expected to provide lucrative opportunities for the market development.

This report segments the BCG vaccines sales market based on drug type, usage, end user, and region to provide a detailed assessment of the market. Based on drug type, it is bifurcated into immune BCG and therapy BCG. On the basis of usage, the market is categorized into tuberculosis and bladder cancer. Based on end user, it is segmented into adults and pediatrics. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

ü The study provides an in-depth analysis of the BCG vaccines sales market along with the current trends and future estimations to elucidate the imminent investment pockets.

ü A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.

ü In-depth analysis of BCG vaccines sales based on drug type such as immune BCG and therapy BCG is carried out in the report.

ü The global BCG vaccines sales market scenario is comprehensively analyzed in accordance to the key cities.

KEY MARKET SEGMENTS

By Drug Type

• Immune BCG

• Therapy BCG

By Usage

• Tuberculosis

• Bladder Cancer

By End User

• Pediatrics

• Adults

By Geography

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o France

o UK

o Italy

o Spain

o Rest of Europe

• Asia-Pacific

o Japan

o China

o India

o Rest of Asia-Pacific

• LAMEA

o Latin America

o Middle East

o Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)

• AJ Vaccines

• China National Pharmaceutical Group Corporation (Sinopharm)

• Greensignal Bio Pharma Limited

• Intervax Ltd

• Japan BCG Laboratory

• Merck & Company Inc

• Sanofi S.A

• Serum Institute of India Pvt. Ltd

• Statens Serum Institute

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

• Shanyao Group

• Shanghai Institute of Biological Products

• BCG Vaccine Laboratory Indi

Chapter: 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. High prevalence of tuberculosis worldwide

3.3.1.2. Rise in number of drug-resistant tuberculosis cases

3.3.2. Opportunity

3.3.2.1. Initiatives by United Nations (UN) for TB prevention worldwide

3.3.3. Challenge

3.3.3.1. Replacement for BCG vaccine

Chapter: 4: BCG VACCINE SALES MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Immune BCG

4.2.1. Key market trends, growth factors, and opportunities

4.3. Therapy BCG

4.3.1. Key market trends, growth factors, and opportunities

Chapter: 5: BCG VACCINE SALES MARKET, BY USAGE

5.1. Overview

5.1.1. Market size and forecast

5.2. Tuberculosis

5.2.1. Key market trends, growth factors, and opportunities

5.3. Bladder Cancer

5.3.1. Key market trends, growth factors, and opportunities

Chapter: 6: GLOBAL BCG VACCINES SALES MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Pediatrics

6.2.1. Key market trends, growth factors, and opportunities

6.3. Adults

6.3.1. Key market trends, growth factors, and opportunities

Chapter: 7: BCG VACCINES SALES MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key growth factors and opportunities

7.2.2. Market size and forecast, by drug type

7.2.3. Market size and forecast, by usage

7.2.4. Market size and forecast, by end user

7.2.5. Market size and forecast, by country

7.2.5.1. U.S. market size and forecast, by drug type

7.2.5.2. U.S. market size and forecast, by usage

7.2.5.3. U.S. market size and forecast, by end user

7.2.5.4. Canada market size and forecast, by drug type

7.2.5.5. Canada market size and forecast, by usage

7.2.5.6. Canada market size and forecast, by end user

7.2.5.7. Mexico market size and forecast, by drug type

7.2.5.8. Mexico market size and forecast, by usage

7.2.5.9. Mexico market size and forecast, by end user

7.2.5.10. Europe

7.2.6. Key market trends growth factors and opportunities

7.2.7. Market size and forecast, by drug type

7.2.8. Market size and forecast, by usage

7.2.9. Market size and forecast, by end user

7.2.10. Market size and forecast, by country

7.2.10.1. Germany market size and forecast, by drug type

7.2.10.2. Germany market size and forecast, by usage

7.2.10.3. Germany market size and forecast, by end user

7.2.10.4. France market size and forecast, by drug type

7.2.10.5. France market size and forecast, by usage

7.2.10.6. France market size and forecast, by end user

7.2.10.7. UK market size and forecast, by drug type

7.2.10.8. UK market size and forecast, by usage

7.2.10.9. UK market size and forecast, by end user

7.2.10.10.Italy market size and forecast, by drug type

7.2.10.11.Italy market size and forecast, by usage

7.2.10.12.Italy market size and forecast, by end user

7.2.10.13.Spain market size and forecast, by drug type

7.2.10.14.Spain market size and forecast, by usage

7.2.10.15.Spain market size and forecast, by end user

7.2.10.16. Rest of Europe market size and forecast, by drug type

7.2.10.17.Rest of Europe market size and forecast, by usage

7.2.10.18.Rest of Europe market size and forecast, by end user

7.3. Asia-Pacific

7.3.1. Key market trends, growth factors, and opportunities

7.3.2. Market size and forecast, by drug type

7.3.3. Market size and forecast, by usage

7.3.4. Market size and forecast, by end user

7.3.5. Market size and forecast, by country

7.3.5.1. Japan market size and forecast, by drug type

7.3.5.2. Japan market size and forecast, by usage

7.3.5.3. Japan market size and forecast, by end user

7.3.5.4. China market size and forecast, by drug type

7.3.5.5. China market size and forecast, by usage

7.3.5.6. China market size and forecast, by end user

7.3.5.7. India market size and forecast, by drug type

7.3.5.8. India market size and forecast, by usage

7.3.5.9. India market size and forecast, by end user

7.3.5.10. Rest of Asia-Pacific market size and forecast, by drug type

7.3.5.11. Rest of Asia-Pacific market size and forecast, by usage

7.3.5.12. Rest of Asia-Pacific market size and forecast, by end user

7.4. LAMEA

7.4.1. Key market trends, growth factors, and opportunities

7.4.2. Market size and forecast, by drug type

7.4.3. Market size and forecast, by usage

7.4.3.1. LAMEA market size and forecast, by end user

7.4.4. Market size and forecast, by country

7.4.4.1. Latin America market size and forecast, by drug type

7.4.4.2. Latin America market size and forecast, by usage

7.4.4.3. Latin America market size and forecast, by end user

7.4.4.4. Middle East market size and forecast, by drug type

7.4.4.5. Middle East market size and forecast, by usage

7.4.4.6. Middle East market size and forecast, by end user

7.4.4.7. Africa market size and forecast, by drug type

7.4.4.8. Africa market size and forecast, by usage

7.4.4.9. Africa market size and forecast, by end user

Chapter: 8: COMPANY PROFILES

8.1. AJ Vaccines

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Product portfolio

8.2. China National Pharmaceutical Group Corporation (Sinopharm)

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Operating business segments

8.2.4. Product portfolio

8.3. GREENSIGNAL BIO PHARMA LIMITED

8.3.1. Company overview

8.3.2. GSBPL: company snapshot

8.3.3. Operating business segments

8.3.4. Key strategic moves and development

8.3.5. Product portfolio

8.4. INTERVAX LTD

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Operating business segments

8.4.4. Product portfolio

8.4.5. Key strategic moves and developments

8.5. JAPAN BCG LABORATORY

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Product portfolio

8.6. MERCK & COMPANY INC

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Operating business segments

8.6.4. Product portfolio

8.6.5. Business performance

8.6.6. Key strategic moves and developments

8.7. SANOFI S.A.

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Product portfolio

8.7.5. Business performance

8.7.6. Key strategic moves and developments

8.8. SERUM INSTITUTE OF INDIA PVT. LTD

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Product portfolio

8.8.5. Key strategic moves and developments

8.9. STATENS SERUM INSTITUTE

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.9.5. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)

TABLE 02. GLOBAL BCG VACCINES SALES MARKET, BY USAGE 2017-2025, ($MILLION)

TABLE 03. GLOBAL BCG VACCINES SALES MARKET, BY USAGE 2017-2025, ($MILLION)

TABLE 04. BCG VACCINES SALES MARKET, BY REGION 2017-2025, ($MILLION)

TABLE 05. NORTH AMERICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 06. NORTH AMERICA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 07. NORTH AMERICA VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 08. NORTH AMERICA BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)

TABLE 09. MEXICO BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 10. U.S. VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 11. U.S. BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 12. CANADA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 13. CANADA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 14. CANADA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 15. MEXICO BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 16. MEXICO VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 17. MEXICO BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 18. EUROPE BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 19. EUROPE VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 20. EUROPE VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 21. EUROPE BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)

TABLE 22. GERMANY BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 23. GERMANY VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 24. GERMANY BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 25. FRANCE BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)

TABLE 26. FRANCE BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 27. FRANCE BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 28. UK BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)

TABLE 29. UK BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION) 58

TABLE 30. UK BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 31. ITALY BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)

TABLE 32. ITALY BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 33. ITALY BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 34. SPAIN BCG VACCINES SALES MARKET, BY DRUG TYPE 2017-2025, ($MILLION)

TABLE 35. SPAIN BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 36. SPAIN BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 37. REST OF EUROPE BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 38. REST OF EUROPE BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 39. REST OF EUROPE BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 40. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 41. ASIA-PACIFIC VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 42. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY END USER 2017-2025, ($MILLION)

TABLE 43. ASIA-PACIFIC BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)

TABLE 44. JAPAN BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 45. JAPAN VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 46. JAPAN VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 47. CHINA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 48. CHINA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 49. CHINA BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 50. INDIA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 51. INDIA VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 52. INDIA VACCINES MARKET, BY END USER 2017-2025, ($MILLION)

TABLE 53. REST OF ASIA-PACIFIC BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 54. REST OF ASIA PACIFIC BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 55. LAMEA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 56. LAMEA BCG VACCINES MARKET, BY USAGE 2017-2025, ($MILLION)

TABLE 57. LAMEA BCG VACCINES SALES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 58. LAMEA BCG VACCINES SALES MARKET, BY COUNTRY, 2017-2025, ($MILLION)

TABLE 59. LATIN AMERICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 60. LATIN AMERICA BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 61. LATIN AMERICA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 62. MIDDLE EAST BCG VACCINES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 63. MIDDLE EAST BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 64. MIDDLE EAST BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 65. AFRICA BCG VACCINES SALES MARKET, BY DRUG TYPE, 2017-2025, ($MILLION)

TABLE 66. AFRICA BCG VACCINES MARKET, BY USAGE, 2017-2025, ($MILLION)

TABLE 67. AFRICA BCG VACCINES MARKET, BY END USER, 2017-2025, ($MILLION)

TABLE 68. AJ VACCINES: COMPANY SNAPSHOT

TABLE 69. AJ VACCINES: OPERATING SEGMENTS

TABLE 70. AJ VACCINES: PRODUCT PORTFOLIO

TABLE 71. SINOPHARM: COMPANY SNAPSHOT

TABLE 72. SINOPHARM: OPERATING SEGMENTS

TABLE 73. SINOPHARM: PRODUCT PORTFOLIO

TABLE 74. GSBPL: PRODUCT PORTFOLIO

TABLE 75. INTERVAX: COMPANY SNAPSHOT

TABLE 76. INTERVAX: PRODUCT PORTFOLIO

TABLE 77. JAPAN BCG LABORATORY: COMPANY SNAPSHOT

TABLE 78. JAPAN BCG LABORATORY: PRODUCT PORTFOLIO

TABLE 79. MERCK: COMPANY SNAPSHOT

TABLE 80. MERCK: OPERATING SEGMENTS

TABLE 81. MERCK: PRODUCT PORTFOLIO

TABLE 82. SANOFI: COMPANY SNAPSHOT

TABLE 83. SANOFI: OPERATING SEGMENTS

TABLE 84. SANOFI: PRODUCT PORTFOLIO

TABLE 85. SERUM: COMPANY SNAPSHOT

TABLE 86. SERUM: PRODUCT PORTFOLIO

TABLE 87. SSI: COMPANY SNAPSHOT

TABLE 88. SSI: OPERATING SEGMENTS

TABLE 89. SSI: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. GLOBAL BCG VACCINES SALES MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. DRIVERS, OPPORTUNITY, & CHALLENGE: GLOBAL BCG VACCINES SALES MARKET

FIGURE 04. MERCK: NET SALES, 2016–2018 ($MILLION)

FIGURE 05. MERCK: REVENUE SHARE BY PRODUCT, 2018 (%)

FIGURE 06. MERCK: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 07. SANOFI: NET SALES, 2015–2017 ($MILLION)

FIGURE 08. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 09. SANOFI: REVENUE SHARE BY REGION, 2017 (%